Phase 0 Clinical Trials in Oncology New Drug Development
Author Information
Author(s): Umesh Chandra Gupta, Sandeep Bhatia, Amit Garg, Amit Sharma, Vaibhav Choudhary
Primary Institution: Fresenius Kabi Oncology Ltd.
Hypothesis
Can phase 0 clinical trials improve the efficiency of new drug development in oncology?
Conclusion
Phase 0 trials can help identify promising drug candidates early in the development process, potentially saving time and resources.
Supporting Evidence
- Phase 0 trials utilize lower drug doses to explore clinical behavior early in drug development.
- These trials help identify promising candidates and eliminate non-promising molecules.
- Phase 0 trials can save significant resources in drug development.
Takeaway
Phase 0 trials are like a quick test to see if a new medicine might work before doing a lot of expensive and time-consuming tests.
Methodology
The article reviews the feasibility, utility, planning, designing, and conduct of phase 0 clinical trials, focusing on ethical issues and industrial perspectives.
Potential Biases
Potential for false negative results leading to discontinuation of promising candidates.
Limitations
Phase 0 trials may not provide evidence for clinical efficacy and safety, and not every drug is suitable for these trials.
Participant Demographics
Participants included patients with advanced malignancies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website